Genmab Presents Three Positive Phase 3 Trials Supporting Potential 2027 Launches
Bitget2026/10/28 17:29- Genmab reported three positive Phase 3 trials, supporting potential approvals and launches beginning in 2027.
- EPKINLY reduced the risk of progression or death by 51% versus R-CHOP in newly diagnosed diffuse large B-cell lymphoma.
- Rina-S cut progression or death risk by 71% versus chemotherapy in platinum-resistant ovarian cancer; overall survival also improved significantly.
- Petosemtamab with pembrolizumab reduced death risk by 50% versus pembrolizumab alone in first-line recurrent or metastatic PD-L1-positive head and neck cancer.
- Estimated peak sales opportunities exceed $3 billion for EPKINLY, exceed $2 billion for Rina-S, and reach multiple billions for petosemtamab.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
